The company said the draw down is to provide working capital to use on a temporary basis.

Natera sold more tests in the quarter, but its revenues dropped due to changes to diagnostic reimbursement codes that lowered NIPT prices.

The Canadian lab services provider uses Natera's proprietary test technology to perform the test at its Toronto laboratory.

The GenomeWeb Index was up around 2 percent, but its performance was well behind the broader stock market.

Prices in Germany for noninvasive prenatal testing have plummeted over the last year, driven by competition and process improvements.

The firm is morphing its massively multiplexed PCR-based method for non-invasive prenatal testing to develop tests for ovarian, breast, and lung cancers.

Biotech stocks fell sharply last month dragging down the GenomeWeb Index almost 8 percent. 

Recent cost analyses funded by Ariosa and Natera found that NIPT could replace conventional screening in the US and be cost-neutral if provided at certain prices.

Chromsomal array testing had a higher diagnostic yield in the study than standard procedures, and could have value as a first step before referring patients to further tests.

The company also plans to submit its Panorama Microdeletion NIPT for US Food and Drug Administration clearance.


US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.